

Silver Benzoate Facilitates the Copper-Catalyzed C–N Coupling of Iodoazoles with Aromatic Nitrogen Heterocycles

Cedric Lozano, Cristian Ramirez, Ny Sin, H el ene M.-F. Viart, Stanley B. Prusiner, Nick A. Paras, and Jay Conrad*

Cite This: *ACS Omega* 2021, 6, 9804–9812


Read Online

ACCESS |

Metrics & More

Article Recommendations

Supporting Information



ABSTRACT: In the literature, C–N coupling methods for the reaction of iodo-oxazole with 2-pyridinone were found to be low yielding. C–N coupling using silver benzoate additives with CuI catalysts and 4,7-dimethoxy-1,10-phenanthroline ligands has been developed to afford synthetically useful yields of the desired heterobicyclic product. The reaction conditions are applied to the coupling of a range of iodo-heterocycles with 2-pyridinone. The coupling of a variety of NH-containing heterocycles with 4-iodo-oxazole is also demonstrated. The use of 2-, 4-, or 5-iodo-oxazole allows for the coupling of pyridinone to each oxazole position.

1. INTRODUCTION


Functionalized oxazoles are frequently featured in drug designs.¹ The scope of the original Gabriel-Robinson oxazole synthesis (Scheme 1a)^{2,3} has been improved through the use of milder dehydrating reagents and improved access to cyclization precursors.^{4,5} These strategies remain, however, inherently less divergent, and single-step methods to diversify substituent

groups on an oxazole core are highly desirable for use in medicinal chemistry. While C–C coupling with oxazoles has been well-developed using metalation,⁶ direct Pd cross-coupling,^{7–11} Suzuki,^{12–14} Negishi,¹⁵ or nickel-catalyzed decarbonylation¹⁶ examples of C–N coupling are less prevalent in the literature. This can be attributed to slow C–N bond forming reductive elimination reactions using electron-rich oxazole electrophiles.¹⁷ Amination of halo-oxazoles at the electron-rich C(4)-position,¹⁸ in particular, is limited to a singular report of Buchwald-Hartwig coupling of piperidines (Scheme 1b).¹⁹ In this work, we report optimization of conditions and scope of the copper-catalyzed coupling of halo-oxazoles with aromatic nitrogen heterocycles.


In the course of our drug discovery efforts, we required a divergent synthesis of *N*-(oxazol-4-yl)pyridones (Scheme 1d). A C–N coupling was envisioned to enable their rapid and modular synthesis. The Buchwald-Hartwig amination reaction²⁰ has been developed into one of the most useful methods to forge C–N bonds.²¹ This includes the coupling of aryl-halides with common nitrogen heterocycles²² or amides using Pd catalysts.²³ Buchwald^{24,25} and Taillefer²⁶ also pioneered the use of auxiliary ligands to expand the scope of C–N coupling via Ullman chemistry. Specifically, Buchwald's use of CuI and

Scheme 1. Synthesis of Functionalized Oxazoles

a) Gabriel-Robinson oxazole synthesis³




b) Example of C(4) amination of 4-halo-oxazole¹⁹



c) Copper catalyzed aryl-N-pyridinone coupling²⁷



d) This work: copper catalyzed iodo-oxazole-N-pyridinone coupling



Received: January 25, 2021

Accepted: February 25, 2021

Published: March 31, 2021




phenanthroline to catalyze the heteroarylation of 2-hydroxy-pyridines bears directly on the present case (Scheme 1c).²⁷




2. RESULTS AND DISCUSSION

Initial attempts to couple 2-pyridinone with 4-iodo-2-phenyloxazole proved unsatisfactory. Two sets of conditions employing Pd catalysts previously applied to couplings of 4-halo-oxazole failed to furnish the desired bicyclic product (Table 1,

Table 1. Optimization of Coupling Conditions



2-pyridone (1.1 equiv) + 4-iodo-2-phenyloxazole (1a) $\xrightarrow[\text{18 h}]{\text{0.1 M DMSO, 125 }^\circ\text{C}}$ Coupled Heterobicyclic (2)

L1 =  L2 =  L3 = 

Entry	Catalyst	%	Ligand	%	Base (2 equiv)	Additive (1 equiv)	Assay Yield (%) ^a
1	Pd ₂ (dba) ₃	5	Xantphos	10	Cs ₂ CO ₃	-	0
2 ^b	Peppi-iPr	5	-	-	NaO ^t Bu	-	0
3	CuI	10	L1	15	K ₃ PO ₄	-	14
4	CuI	10	L2	15	K ₃ PO ₄	-	<5
5	CuI	10	L3	15	K ₃ PO ₄	-	0
6	CuI	10	TMEDA	15	K ₃ PO ₄	-	0
7	CuI	10	L1	15	K ₃ PO ₄	Ag ₂ CO ₃	23
8	CuI	10	L1	15	NaO ^t Bu	Ag ₂ CO ₃	31
9	CuI	10	L1	15	KOH	Ag ₂ CO ₃	39
10	CuI	10	L1	15	Cs ₂ CO ₃	Ag ₂ CO ₃	49
11	CuI	10	L1	15	K ₂ CO ₃	Ag ₂ CO ₃	53
12	CuI	10	L1	15	K ₂ CO ₃	AgOBz	63
13 ^c	CuI	10	L1	15	K ₂ CO ₃	AgOBz	72
14 ^d	CuI	10	L1	15	K ₂ CO ₃	AgOBz	81 (77) ^e
15 ^{d,f}	CuI	10	L1	15	K ₂ CO ₃	AgOBz	20 ^e

^aAverage HPLC assay yield for two reactions using an internal standard. ^bTHF, 40 °C. ^c0.05 M. ^d0.025 M. ^eIsolated yield. ^fUsing 4-bromo-2-phenyloxazole in place of 4-iodo-2-phenyloxazole 1a.

entries 1–2). The Buchwald group has also shown that use of the CuI catalyst with the 4,7-dimethoxy-1,10-phenanthroline ligand (L1) is an optimal ligand for heterocycle coupling,²⁸ and in our case, the yield improved to 14% (entry 3). Switching the ligand to phenanthroline provided <5% product (entry 4). Amide coupling conditions using TMEDA or *trans*-1,2-methylamino-cyclohexane (L3) also did not provide any of the desired product (entry 5, 6).

The use of silver additives to increase the reaction yield for the palladium-catalyzed direct arylation of aryl iodides has been reported. By sequestering iodide with Ag₂CO₃ rather than K₂CO₃ the yield is increased from 64 to 99%.²⁹ For copper catalysis, direct arylation of benzodithiophene-*S,S*-tetraoxide with aryl iodides was found to be most efficient with Ag₂CO₃.³⁰ In a subsequent computation study, it was determined that the Ag additive reduces the rate-limiting Ph–I insertion through a Ag–I interaction and oxidative addition of Ph–I on Ag.³¹ For Cu-catalyzed amide arylations using excess bidentate ligands, Ar–I insertion is rate-limiting.³² We therefore attempted to increase the yield of the oxazole amide coupling by the addition of Ag₂CO₃, and a modest

increase in the yield to 23% was observed (entry 7). We then screened other bases (entries 8–11) and found K₂CO₃ to be best (entry 11, 53%). We then recognized that the solubility of Ag₂CO₃ could be limiting the reaction and switched to AgOBz; the yield increased to 63% (entry 12). By lowering the reaction concentration, we saw further improvement in the reaction yield, 72% at 0.05 M (entry 13) and 81% yield at 0.025 M (entry 14). We then isolated the product in 77% yield. Use of 4-bromo-2-phenyloxazole in place of 4-iodo-2-phenyloxazole is lower yielding (entry 15, 20%).

The scope of N-heterocycles beyond 2-pyridinone was then investigated (Figure 1). 3-Substituted 2-pyridinones afforded modest yields (3: Br, 55%; 4: MeO, 54%; 5: EtO, 42%; 6: Me, 48%; and 7: F, 47%).

Pyridazin-3(2*H*)-one (8, 54%) or 6-methylpyridazin-3(2*H*)-one (9, 58%) coupled in a similar yield. Pyrazole (10, 45%) or




Figure 1. Scope of the N-heterocycle coupling partner.

4-iodopyrazole (**11**, 31%) proved more challenging. Imidazole **12** coupled well (77%); however, 4-bromoimidazole **13** was less efficiently coupled (53%). 1,2,4-Triazole (**14**, 46%) or 5-methylpyrimidine-2,4-dione (**15**, 51%) both coupled at the N1-position. The pyridinone regioisomer 3-bromopyridin-4-one coupled in 44% yield (**16**). Next, we tested the scope of fused bicyclic pyridinones. While imidazo[1,2-*a*]pyrazin-8-one (**18**, 36%) proved to be one of the most challenging substrates, thieno[2,3-*c*]pyridin-7-one (**19**, 76%) or furo[2,3-*c*]pyridin-7(6*H*)-one (**20**, 58%) worked well. Indazole (**21**, 31%) was lower yielding than 6-chloro-indole (**22**, 56%). Benzimidazole (**23**, 65%) or 6-aza-indole (**24**, 62%) coupled in a moderate yield.

The reaction of 2-pyridinone was then explored with different iodo-heterocycles (Figure 2). 2-Iodo-benzoxazole





Figure 2. Scope of iodo-heterocycle coupling with 2-pyridone to provide *N*-pyridin-2-one heterocycles.

(**25**, 53%), 2-iodo-benzthiazole (**26**, 77%), 2-iodo-benzthiophene (**27**, 48%), 2-iodo-5-phenyl-1,3,4-oxadiazole (**28**, 60%), 3-iodo-1-phenyl-pyrazole (**29**, 65%), 5-iodo-2-phenylthiazole (**30**, 41%), and 5-bromo-2-iodo-1-methyl-1*H*-benzo[*d*]imidazole (**31**, 47%) were all coupled successfully.

The coupling of iodo-oxazole regioisomers with 2-pyridinone is presented in Figure 3. Use of 2-iodo-5-phenyl-oxazole provides the 2-substituted product **32** in 63% yield. Use of 5-iodo-2-phenyloxazole as the substrate provides the 5-substituted product **33** in 49% yield. Using this method, we can generate all three oxazole-pyridinone regioisomers. Sterically encumbered 4-iodo-5-methyl-2-phenyloxazole is also competent in the coupling reaction to provide **34** in 41% yield.

3. CONCLUSIONS

In summary, by using AgOBz as an additive, we have been able to extend the scope of the Buchwald's copper-catalyzed aryl amine coupling reaction to include the coupling of iodo-azoles with NH-containing heterocycles. We have demonstrated that these coupling conditions can be used to couple oxazole to a diverse range of heterocycles of pharmaceutical interest. High selectivity for coupling of aromatic iodides allows incorporation of additional aromatic halides, I (**11**), Br (**3**, **13**, **16**), or




Figure 3. Synthesis of oxazole positional isomers.

Cl (**22**), that can subsequently be used for further derivatization.

4. EXPERIMENTAL SECTION

4.1. General Information. All reactions were conducted under an atmosphere of air unless otherwise indicated, using a Teflon-coated magnetic stir bar at the temperature given. Commercial reagents and anhydrous solvents were used without further purification. Organic solvents, silver benzoate, 4,7-dimethoxyphenanthroline, potassium carbonate, copper(I) iodide, pyridone, and 3-iodo-*N*-phenyl-pyrazole (**1f**) were purchased from Sigma-Aldrich. 2-Iodobenzothiazole (**1d**) was purchased from Frontier Scientific. Reactions were monitored by liquid chromatography-mass spectroscopy (LC-MS) (Agilent Technologies G6100 Series LC/MSD Single Quad). Flash chromatography was carried out on a CombiFlash R_f purification system using RediSep Rf Gold silica gel (20–40 μm), purchased from Teledyne Isco, Inc. Preparative LC was performed on a Teledyne Isco CombiFlash EZ Prep equipped with a Luna 5 μm 100 Å 100 × 30 mm LC column. Organic solutions were concentrated under reduced pressure on a Heidolph rotary evaporator. ¹H, ¹³C{¹H}, ¹⁹F, and ³¹P NMR spectra were recorded on a Bruker Avance (400 MHz) spectrometer. ¹H and ¹³C{¹H} spectra are internally referenced to residual proton solvent signals (DMSO referenced at δ 2.50 ppm for ¹H and δ 39.52 ppm for ¹³C; chloroform referenced at δ 7.26 ppm for ¹H and δ 77.16 ppm for ¹³C). Chemical shifts (δ) are reported in parts per million (ppm). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. High resolution mass spectral data were determined on a Synapt G2 QTOF mass spectrometer.

4.2. Synthesis of 4-Iodo-2-phenyloxazole. 1,3-Oxazole (1.00 mL, 14.9 mmol, 1 equiv) was dissolved into a mixture of anhydrous THF (6.4 mL) and anhydrous DMPU (5.2 mL) and cooled to −78 °C. LHMDS (32 mL, 32 mmol, 2.1 equiv) was then added dropwise and stirred for 1 h. After this time, solid iodine (7.7 g, 30 mmol, 2 equiv) was added to the reaction mixture and stirred for an additional 30 min at −78 °C. The cooling bath was then removed, and the reaction mixture was left to warm to room temperature and stirred for

48 h under a low positive pressure of N₂. The reaction mixture was then poured into a mixture of aqueous Na₂S₂O₃ (100 mL) and diethyl ether (100 mL). The organic layer was washed with brine (100 mL) and dried over MgSO₄. After filtration, the solvent was removed in vacuo. The residue was purified by flash chromatography (silica, hexanes/EtOAc, 9:1) to afford 2,4-diiodooxazole (3.701 g, 77% yield). Characterization matches with literature values.³³

Under nitrogen, Pd(OAc)₂ (6.12 mg, 0.027 mmol, 0.030 equiv) and 1,3,5-triaza-7-phosphaadamantane (9.44 mg, 0.054 mmol, 0.050 equiv) were added to degassed acetonitrile (0.45 M). After stirring for 5 min, this solution was transferred to a separate vessel under nitrogen containing 2,4-diiodooxazole (350 mg, 1.00 mmol, 1.0 equiv), phenylboronic acid (146 mg, 1.20 mmol, 1.2 equiv), and potassium hydrogen phosphate (695 mg, 3.27 mmol, 3.3 equiv). The sealed vessel was heated at 60 °C for 18 h. Upon cooling to room temperature, LC–MS showed 100% conversion of the starting material, 19.5:1 mono:bis product ratio, and > 20:1 C2:C4 product isomer ratio. The reaction mixture was filtered and the solid was washed with DCM. The solvents were removed by rotary evaporation and the title compound was purified by column chromatography (silica gel, EtOAc/hexane) to give a white solid (502 mg, 42% yield). Spectra are consistent with reported literature.¹⁴

4.3. General Procedures for the Synthesis of Heteroaryl Halides.

4.3.1. Heteroaryl Halide Synthesis Procedure A. Modified from a literature procedure.³⁴ To a flame-dried vial was added 1,3-azole (2.52 mmol, 1.0 equiv), 1,10-phenanthroline (2.52 mmol, 1.0 equiv), LiO^tBu (5.04 mmol, 2.0 equiv), CuBr₂ (0.126 mmol, 0.05 equiv), and iodine (3.78 mmol, 1.5 equiv). Dry 1,4-dioxane (2 mL) was then added to the mixture and heated to 80 °C. The mixture was cooled to room temperature and filtered through a short pad of silica gel. The silica gel was washed with EtOAc (20 mL) and the combined filtrate was concentrated under reduced pressure then purified by silica gel column chromatography to afford the title compound(s).

4.3.2. Heteroaryl Halide Synthesis Procedure B. To a flame-dried vial was added 1,3-azole (6.20 mmol, 1.0 equiv), *N*-iodosuccinimide (13.64 mmol, 2.2 equiv), and chloroform (4 mL). To the reaction mixture was added three drops of trifluoroacetic acid and then heated to 65 °C. Once the starting material was consumed, the reaction was cooled then diluted with dichloromethane and washed with aqueous sodium bicarbonate and brine. The organic phase was then dried over sodium sulfate and filtered. The filtrate was concentrated and the product purified by silica gel column chromatography to yield the title compound(s).

4.3.3. 2-Iodobenzo[d]oxazole (1b). General Procedure A was used to obtain **1b** as a white solid, yield 89% (549 mg). Analytical data are consistent with the values reported in the literature.³⁵

4.3.4. 2-Iodobenzo[d]thiazole (1c). General Procedure A was used to obtain **1c** as a white solid, yield 55% (362 mg). Analytical data are consistent with the values reported in the literature.³⁶

4.3.5. 2-Iodo-5-phenyl-1,3,4-oxadiazole (1e). General Procedure A was used to obtain **1e** as a white solid, yield 76% (521 mg). Analytical data are consistent with the values reported in the literature.³⁷

4.3.6. 5-Iodo-2-phenylthiazole (1g). General Procedure B was used to obtain **1g** as a white solid, 63% yield (1.12 g). ¹H

NMR (400 MHz, CDCl₃): δ 7.43–7.46 (m, 3H), 7.87 (s, 1H), 7.87–7.90 (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 70.05, 126.44, 129.10, 130.50, 133.00, 151.46, 173.62 HRMS (ESI), C₉H₆INSH [M + H]⁺ + calculated *m/z* 287.9344; found *m/z* 287.9336.

4.3.7. 2-Iodo-5-bromo-1-methyl-1H-benzo[d]imidazole (1h). General Procedure A was used to obtain **1h** as a white solid, 48% yield (408 mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ 3.76 (s, 3H), 7.38 (dd, *J* = 8.56, 1.71 Hz, 1H), 7.59 (d, *J* = 8.56 Hz, 1H), 7.79 (d, *J* = 1.71 Hz, 1H). ¹³C{¹H} NMR (101 MHz, DMSO-*d*₆): δ 34.17, 110.29, 112.69, 114.57, 120.91, 125.63, 135.70, 146.38. HRMS (ESI), C₈H₆BrIN₂H [M + H]⁺ calculated *m/z* 336.8837; found 336.8835.

4.3.8. 2-Iodo-5-phenyloxazole (1i). General Procedure B was used to obtain **1i** as a white solid. Yield 52% (873 mg). Analytical data are consistent with the values reported in the literature.³⁸

4.3.9. 5-Iodo-2-phenyloxazole (1j). General Procedure B was used to obtain **1j** as a white solid. Yield 64% (1.08 g). ¹H NMR (400 MHz, CDCl₃): δ 7.25 (s, 1H), 7.43–7.47 (m, 3H), 7.99–8.03 (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 86.65, 126.21, 126.70, 128.84, 130.79, 136.98, 166.42 HRMS (ESI) C₉H₆INOH [M + H]⁺ calculated *m/z* 271.9572; found *m/z* 271.9576.

4.3.10. 4-Iodo-5-methyl-2-phenyl-1,3-oxazole (1k). 5-Methyl-2-phenyl-oxazole was synthesized using a literature procedure.³⁹ 5-Methyl-2-phenyl-oxazole (150 mg, 0.94 mmol) was then dissolved in THF (0.2 M) and cooled to –78 °C. To the solution was added a solution of *n*-butyllithium (2.5 M, 1.1 equiv) and the reaction mixture stirred for 1 h. Solid I₂ (1 equiv) was then added to the solution and the reaction was allowed to stir for another hour. The reaction mixture was then diluted with water, extracted with CH₂Cl₂ (3×), washed once with aqueous brine, and dried over Na₂SO₄ to afford a white powder (41% yield, 110 mg). ¹H NMR (400 MHz, CDCl₃): δ 2.42 (s, 3H), 7.42–7.46 (m, 3H), 7.97–8.02 (m, 2H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 11.22, 81.73, 126.03, 126.73, 128.78, 130.49, 150.82, 161.88. HRMS (ESI) C₁₀H₈INOH [M + H]⁺ calculated *m/z* 285.9729; found *m/z* 285.9724.

4.3.11. General Procedure for C–N Coupling. To a 40 mL vial charged with a Teflon stir bar was added heteroaryl iodide 1a–1k (0.1 mmol, 1.0 equiv), copper(I) iodide (0.01 mmol, 0.10 equiv), 4,7-dimethoxy-1,10-phenanthroline (0.015 mmol, 0.15 equiv), silver(I) benzoate (0.1 mmol, 1 equiv), potassium carbonate (0.20 mmol, 2.0 equiv), aromatic heterocycle NH (1.1 equiv), and DMSO (3 mL, 0.033 M). The reaction mixture was stirred at 125 °C for 18 h, unless stated otherwise. The reaction was filtered through a pad of celite and rinsed with EtOAc, the filtrate was diluted with H₂O (3 mL), extracted with EtOAc (3 × 10 mL), washed again with saturated aqueous LiCl (5 mL), and dried over Na₂SO₄ then filtered off. The crude mixture was then concentrated, and the title compound purified via column chromatography using a heptane/ethyl acetate solvent system unless stated otherwise.

4.3.12. 4-Pyridonyl-2-phenyloxazole (2). The title compound was synthesized according to the general procedure for C–N coupling using pyridin-2(1H)-one (10.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **2** as a white solid in 77% yield (18.4 mg). ¹H NMR (400 MHz, CDCl₃): δ 6.42 (t, *J* = 6.72 Hz, 1H), 6.73 (d, *J* = 9.05 Hz, 1H), 7.42 (ddd, *J* = 9.05, 6.60, 1.96 Hz, 1H), 7.46–7.55 (m, 3H), 8.04–8.14 (m,

2H), 8.61 (dd, $J = 7.21, 1.83$ Hz, 1H), 8.74 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 106.53, 121.06, 126.51, 126.79, 128.89, 130.44, 130.90, 132.89, 137.74, 138.84, 158.99, 160.73. HRMS (ESI) $\text{C}_{14}\text{H}_{10}\text{N}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 261.0640; found m/z 261.0628.

4.3.13. 3-Bromo-1-(2-phenyl-1,3-oxazol-4-yl)pyridin-2(1H)-one (3). The title compound was synthesized according to the general procedure for C–N coupling using 3-bromopyridine-2(1H)-one (19.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **3** as a white solid in 55% yield (17.3 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.34 (t, $J = 7.21$ Hz, 1H), 7.49–7.53 (m, 3H), 7.83 (dd, $J = 7.09, 1.71$ Hz, 1H), 8.08–8.12 (m, 2H), 8.66 (dd, $J = 7.09, 1.71$ Hz, 1H), 8.77 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 106.26, 116.08, 126.13, 126.17, 128.58, 130.39, 130.68, 132.05, 137.33, 140.29, 156.40, 158.77. HRMS (ESI) $\text{C}_{14}\text{H}_9\text{N}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 338.9745; found m/z 338.9748.

4.3.14. 3-Methoxy-1-(2-phenyl-1,3-oxazol-4-yl)pyridin-2(1H)-one (4). The title compound was synthesized according to the general procedure for C–N coupling using 3-methoxy-2(1H)-pyridinone (14.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **4** as a white solid in 54% yield (14.5 mg). ^1H NMR (400 MHz, CDCl_3): δ 3.85–3.90 (m, 3H), 6.34 (t, $J = 7.34$ Hz, 1H), 6.67 (dd, $J = 7.34, 1.47$ Hz, 1H), 7.46–7.53 (m, 3H), 8.06–8.13 (m, 2H), 8.23 (dd, $J = 7.21, 1.59$ Hz, 1H), 8.77 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 56.05, 105.51, 111.21, 123.81, 126.46, 126.83, 128.86, 130.50, 130.82, 137.82, 149.83, 156.31, 158.85. HRMS (ESI) $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_3\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 291.0746; found m/z 291.0742.

4.3.15. 3-Ethoxy-1-(2-phenyl-1,3-oxazol-4-yl)pyridin-2(1H)-one (5). The title compound was synthesized according to the general procedure for C–N coupling using 3-ethoxy-2(1H)-pyridinone (15.2 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **5** as a white solid in 42% yield (15.3 mg). ^1H NMR (400 MHz, CDCl_3): δ 1.53 (t, $J = 6.97$ Hz, 3H), 4.06 (q, $J = 7.09$ Hz, 2H), 6.32 (t, $J = 7.34$ Hz, 1H), 6.66 (dd, $J = 7.34, 1.22$ Hz, 1H), 7.45–7.54 (m, 3H), 8.07–8.14 (m, 2H), 8.23 (dd, $J = 7.34, 1.47$ Hz, 1H), 8.77 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 14.52, 64.53, 105.61, 112.09, 123.64, 126.46, 126.87, 128.86, 130.47, 130.81, 137.91, 149.09, 156.42, 158.83. HRMS (ESI) $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_3\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 305.0902; found m/z 305.0898.

4.3.16. 3-Methyl-1-(2-phenyl-1,3-oxazol-4-yl)pyridin-2(1H)-one (6). The title compound was synthesized according to the general procedure for C–N coupling using 3-methylpyridine-2(1H)-one (12.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **6** as a white solid in 48% yield (12.0 mg). ^1H NMR (400 MHz, CDCl_3): δ 2.25 (s, 3H), 6.34 (t, $J = 6.97$ Hz, 1H), 7.29 (s, 1H), 7.46–7.54 (m, 3H), 8.07–8.14 (m, 2H), 8.50 (dd, $J = 7.21, 1.10$ Hz, 1H), 8.75 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 17.22, 106.45, 126.47, 126.85, 128.86, 129.80, 130.24, 130.43, 130.83, 136.08, 138.04, 158.88, 161.25. HRMS (ESI) $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 275.0797; m/z found 275.0788.

4.3.17. 3-Fluoro-1-(2-phenyl-1,3-oxazol-4-yl)pyridin-2(1H)-one (7). The title compound was synthesized according to the general procedure for C–N coupling using 3-fluoropyridin-2(1H)-one (12.4 mg) as the heterocycle. The product was purified by silica gel column chromatography

Hep:EtOAc 1:1 to provide **7** as a white solid in 47% yield (12.2 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.34 (td, $J = 7.34, 4.65$ Hz, 1H), 7.17 (ddd, $J = 9.05, 7.34, 1.71$ Hz, 1H), 7.48–7.53 (m, 3H), 8.07–8.12 (m, 2H), 8.42 (dt, $J = 7.34, 1.47$ Hz, 1H), 8.76 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 104.42, 104.48, 119.09, 119.26, 126.54, 126.57, 128.18, 128.23, 128.93, 130.67, 131.08, 159.17. HRMS (ESI) $\text{C}_{14}\text{H}_9\text{FN}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 279.0546; found m/z 279.0541.

4.3.18. 2-(2-Phenyl-1,3-oxazol-4-yl)pyridazin-3(2H)-one (8). The title compound was synthesized according to the general procedure for C–N coupling using pyridazin-3(2H)-one (11.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **8** as a white solid in 54% yield (12.9 mg). ^1H NMR (400 MHz, CDCl_3): δ 7.12 (dd, $J = 9.54, 1.47$ Hz, 1H), 7.31 (dd, $J = 9.54, 3.67$ Hz, 1H), 7.46–7.52 (m, 3H), 8.13–8.20 (m, 3H), 8.69 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 126.62, 126.84, 128.78, 130.13, 130.51, 130.77, 131.01, 137.54, 139.69, 158.53, 160.12. HRMS (ESI) $\text{C}_{13}\text{H}_9\text{N}_3\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 262.0592; found m/z 262.0591.

4.3.19. 6-Methyl-2-(2-phenyl-1,3-oxazol-4-yl)pyridazin-3(2H)-one (9). The title compound was synthesized according to the general procedure for C–N coupling using 6-methylpyridazin-3(2H)-one (12 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **9** as colorless oil in 58% yield (14.6 mg). ^1H NMR (400 MHz, CDCl_3): δ 2.55 (s, 3H), 7.05 (d, $J = 9.54$ Hz, 1H), 7.21 (d, $J = 9.29$ Hz, 1H), 7.46–7.52 (m, 3H), 8.15 (dd, $J = 6.60, 2.93$ Hz, 2H), 8.63 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 21.37, 126.57, 126.84, 128.75, 129.97, 130.85, 131.00, 133.00, 139.49, 146.31, 158.32, 160.15. HRMS (ESI) $\text{C}_{14}\text{H}_{11}\text{N}_3\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 276.0749; found m/z 276.0738.

4.3.20. 2-Phenyl-4-(1H-pyrazol-1-yl)-1,3-oxazole (10). The title compound was synthesized according to the general procedure for C–N coupling using 1H-pyrazole (7.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **10** as a white solid in 45% yield (9.4 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 6.56 (t, $J = 1.96$ Hz, 1H), 7.57–7.60 (m, 3H), 7.78–7.80 (m, 1H), 8.01–8.06 (m, 2H), 8.30 (d, $J = 2.45$ Hz, 1H), 8.53 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, $\text{DMSO}-d_6$): δ 107.87, 126.54, 126.58, 127.16, 128.90, 129.78, 131.77, 141.38, 142.27, 160.31. HRMS (ESI) $\text{C}_{12}\text{H}_9\text{N}_3\text{O}$ $[\text{M} + \text{Na}]^+$ m/z 234.0643; found m/z 234.0634.

4.3.21. 4-(4-Iodo-1H-pyrazol-1-yl)-2-phenyl-1,3-oxazole (11). The title compound was synthesized according to the general procedure for C–N coupling using 4-iodo-1H-pyrazole (21.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **11** as a white solid in 31% yield (10.4 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.56–7.61 (m, 3H), 7.90 (s, 1H), 8.04 (dd, $J = 6.60, 2.93$ Hz, 2H), 8.48 (s, 1H), 8.60 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, $\text{DMSO}-d_6$): δ 60.85, 126.43, 126.61, 127.73, 129.80, 131.87, 133.29, 140.72, 146.96, 160.36. HRMS (GC CI-MS) $\text{C}_{12}\text{H}_8\text{IN}_3\text{O}$ $[\text{M}]^{+\bullet}$ calculated m/z 336.9712; found m/z 336.9699.

4.3.22. 4-(1H-imidazol-1-yl)-2-phenyl-1,3-oxazole (12). The title compound was synthesized according to the general procedure for C–N coupling using 1H-imidazole (7.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **12** as a white solid in 77% yield (16.3 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ

ppm 7.15 (br s, 1H), 7.57–7.61 (m, 3H), 7.70 (br s, 1H), 8.02–8.07 (m, 2H), 8.22 (s, 1H), 8.65 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO-*d*₆): δ 118.16, 126.43, 126.62, 127.60, 129.77, 130.00, 131.84, 135.89, 138.21, 160.51. HRMS (ESI) $\text{C}_{12}\text{H}_9\text{N}_3\text{OH} [\text{M} + \text{H}]^+$ calculated m/z 212.0824; found m/z 212.0827.

4.3.23. 4-(4-Bromo-1H-imidazol-1-yl)-2-phenyl-1,3-oxazole (13). The title compound was synthesized according to the general procedure for C–N coupling using 4-bromo-1H-imidazole (16.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 13 as a white solid in 53% yield (15.2 mg). ^1H NMR (400 MHz, DMSO-*d*₆): δ 7.58–7.61 (m, 3H), 7.90 (s, 1H), 8.01–8.05 (m, 2H), 8.24 (s, 1H), 8.65 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO-*d*₆): δ 116.21, 117.60, 126.27, 126.67, 128.30, 129.80, 131.98, 136.24, 137.44, 160.59. HRMS (ESI) $\text{C}_{12}\text{H}_8\text{BrN}_3\text{OH} [\text{M} + \text{H}]^+$ calculated m/z 289.9929; found m/z 289.9933. The assignment is based on analogy to arylations of 4-bromo-1H-imidazole as the heterocycle.⁴⁰

4.3.24. 1-(2-Phenyl-1,3-oxazol-4-yl)-1H-1,2,4-triazole (14). The title compound was synthesized according to the general procedure for C–N coupling using 1,2,4-triazole (7.6 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 14 as a white solid in 46% yield (9.8 mg). ^1H NMR (400 MHz, DMSO-*d*₆): δ 7.57–7.62 (m, 3H), 8.02–8.07 (m, 2H), 8.31 (s, 1H), 8.70 (s, 1H), 9.13 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 126.27, 126.70, 129.22, 129.84, 132.04, 138.35, 143.58, 153.42, 160.77. HRMS (ESI) $\text{C}_{11}\text{H}_8\text{N}_4\text{OH} [\text{M} + \text{H}]^+$ calculated m/z 213.0776; found m/z 213.0776.

4.3.25. 5-Methyl-1-(2-phenyl-1,3-oxazol-4-yl)pyrimidine-2,4(1H,3H)-dione (15). 3-Benzoyl-5-methyl-2,4(1H,3H)-pyrimidinedione was synthesized via a literature procedure⁴¹ and was used as the heterocycle (25.0 mg) coupling partner. The title compound was synthesized according to the general procedure for C–N coupling. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 15 as a white solid in 51% yield (13.6 mg). ^1H NMR (400 MHz, DMSO-*d*₆): δ 1.91 (d, J = 0.98 Hz, 3H), 7.56–7.60 (m, 3H), 8.02–8.07 (m, 2H), 8.25 (d, J = 1.22 Hz, 1H), 8.44 (s, 1H), 11.76 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO-*d*₆): δ 12.61, 111.05, 126.46, 126.57, 129.22, 129.75, 131.75, 136.06, 137.09, 149.13, 158.91, 163.91. HRMS (ESI) $\text{C}_{14}\text{H}_{11}\text{N}_3\text{O}_3\text{Na} [\text{M} + \text{Na}]^+$ calculated m/z 292.0698; found m/z 292.0684.

4.3.26. 3-Bromo-1-(2-phenyl-1,3-oxazol-4-yl)pyridin-4(1H)-one (16). The title compound was synthesized according to the general procedure for C–N coupling using 3-bromopyridine-4(1H)-one (19.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 16 as a white solid in 44% yield (13.8 mg). ^1H NMR (400 MHz, CDCl₃): δ 6.61 (d, J = 7.58 Hz, 1H), 7.49–7.57 (m, 3H), 7.87 (s, 1H), 7.92 (dd, J = 7.83, 2.20 Hz, 1H), 8.07 (dd, J = 7.58, 1.71 Hz, 2H), 8.41 (d, J = 2.20 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 116.55, 117.10, 124.59, 125.95, 126.70, 129.10, 131.74, 135.57, 136.59, 141.82, 161.65, 173.62. HRMS (ESI) $\text{C}_{14}\text{H}_9\text{BrN}_2\text{O}_2\text{H} [\text{M} + \text{H}]^+$ calculated m/z 316.9926; found m/z 316.9928.

4.3.27. 8-Methyl-6-(2-phenyl-1,3-oxazol-4-yl)imidazo[1,2-*c*]pyrimidin-5(6H)-one (17). The title compound was synthesized according to the general procedure for C–N coupling using 8-methyl-6-imidazo[1,2-*c*]pyrimidin-5(6H)-one (16.3 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide

17 as a white solid in 67% yield (18.2 mg). ^1H NMR (400 MHz, CDCl₃): δ 2.48 (d, J = 1.22 Hz, 3H), 7.48 (d, J = 1.47 Hz, 1H), 7.52 (quin, J = 3.18 Hz, 3H), 7.85 (d, J = 1.47 Hz, 1H), 8.09–8.14 (m, 2H), 8.19 (d, J = 1.22 Hz, 1H), 8.46 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 13.28, 109.03, 113.47, 124.37, 126.44, 126.53, 128.53, 128.89, 131.03, 132.82, 137.33, 144.13, 145.56, 159.37. HRMS (ESI) calculated for $\text{C}_{16}\text{H}_{12}\text{N}_4\text{O}_2\text{H} [\text{M} + \text{H}]^+$ 293.1039 found 293.1035.

4.3.28. 7-(2-Phenyl-1,3-oxazol-4-yl)imidazo[1,2-*a*]pyrazin-8(7H)-one (18). The title compound was synthesized according to the general procedure for C–N coupling using imidazo[1,2-*a*]pyrazin-8(7H)-one (17.0 mg) as the heterocycle. The product was purified by silica gel column chromatography DCM/methanol 90:10 to provide 18 as a white solid in 36% yield (9.2 mg). ^1H NMR (400 MHz, DMSO-*d*₆): δ 7.57 (s, 1H), 7.59–7.62 (m, 3H), 7.83 (d, J = 6.11 Hz, 1H), 7.95 (s, 1H), 7.98 (d, J = 6.11 Hz, 1H), 8.08 (dd, J = 6.60, 2.93 Hz, 2H), 8.77 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO-*d*₆): δ 109.20, 115.92, 118.71, 126.46, 126.62, 129.81, 130.15, 131.82, 133.70, 136.82, 137.33, 151.37, 158.79. HRMS (ESI) $\text{C}_{15}\text{H}_{10}\text{N}_4\text{O}_2\text{Na} [\text{M} + \text{Na}]^+$ calculated m/z 301.0702; found m/z 301.0699.

4.3.29. 6-(2-Phenyl-1,3-oxazol-4-yl)thieno[2,3-*c*]pyridin-7(6H)-one (19). The title compound was synthesized according to the general procedure for C–N coupling using thieno[2,3-*c*]pyridin-7(6H)-one (16.6 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 19 as a white solid in 76% yield (22.3 mg). ^1H NMR (400 MHz, CDCl₃): δ 6.88 (d, J = 7.34 Hz, 1H), 7.26–7.30 (m, 2H), 7.51 (m, J = 3.30 Hz, 3H), 7.77 (d, J = 5.14 Hz, 1H), 8.10–8.15 (m, 1H), 8.54 (d, J = 7.34 Hz, 1H), 8.73 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 103.84, 124.42, 126.44, 126.82, 128.67, 128.85, 129.74, 130.08, 130.80, 134.16, 138.00, 144.50, 156.76, 158.87. HRMS (ESI) $\text{C}_{16}\text{H}_{10}\text{N}_2\text{O}_2\text{SNa} [\text{M} + \text{Na}]^+$ m/z 317.0361; found m/z 317.0356.

4.3.30. 6-(2-Phenyl-1,3-oxazol-4-yl)furo[2,3-*c*]pyridin-7(6H)-one (20). The title compound was synthesized according to the general procedure for C–N coupling using furo[2,3-*c*]pyridin-7(6H)-one (14.8 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 20 as a white solid in 58% yield (16.1 mg). ^1H NMR (400 MHz, CDCl₃): δ 6.69–6.75 (m, 2H), 7.49–7.53 (m, 3H), 7.82 (d, J = 1.96 Hz, 1H), 8.09–8.14 (m, 2H), 8.47 (d, J = 7.34 Hz, 1H), 8.76 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 101.19, 107.47, 126.49, 126.84, 128.24, 128.89, 129.96, 130.86, 132.30, 137.88, 143.38, 148.97, 151.85, 158.89. HRMS (ESI) $\text{C}_{16}\text{H}_{10}\text{N}_2\text{O}_3\text{Na} [\text{M} + \text{Na}]^+$ calculated m/z 301.0589; found m/z 301.0588.

4.3.31. 1-(2-Phenyl-1,3-oxazol-4-yl)-1H-indazole (21). The title compound was synthesized according to the general procedure for C–N coupling using 1H-indazole (13.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide 21 as a white solid in 31% yield (8.1 mg). ^1H NMR (400 MHz, DMSO-*d*₆): δ 7.30–7.35 (m, 1H), 7.57–7.60 (m, 1H), 7.61 (d, J = 2.20 Hz, 3H), 7.89–7.93 (m, 1H), 8.12–8.15 (m, 2H), 8.37–8.40 (m, 1H), 8.44 (s, 1H), 8.64 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO-*d*₆): δ 112.53, 121.89, 122.75, 124.92, 126.60, 126.74, 127.54, 128.51, 129.81, 131.71, 137.44, 138.84, 141.85, 160.28. HRMS (ESI) $\text{C}_{16}\text{H}_{11}\text{N}_3\text{ONa} [\text{M} + \text{Na}]^+$ calculated m/z 284.0800; found m/z 284.0807. The assignment based on analogy to literature arylation of indazoles.^{42,43}

4.3.32. 6-Chloro-1-(2-phenyl-1,3-oxazol-4-yl)-1H-indole (22). The title compound was synthesized according to the general procedure for C–N coupling using 6-chloro-1H-indole (17.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **22** as a white solid in 54% yield (15.8 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.69 (d, $J = 3.42$ Hz, 1H), 7.19 (dd, $J = 8.44$, 1.83 Hz, 1H), 7.51–7.54 (m, 3H), 7.58 (d, $J = 8.31$ Hz, 1H), 7.61 (d, $J = 3.42$ Hz, 1H), 7.81 (d, $J = 1.47$ Hz, 1H), 7.90 (s, 1H), 8.13–8.16 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 104.71, 111.72, 121.68, 121.96, 125.12, 125.53, 126.57, 126.87, 126.95, 128.08, 128.92, 130.98, 135.45, 139.97, 160.63. HRMS (ESI) $\text{C}_{17}\text{H}_{11}\text{ClN}_2\text{O}$ $[\text{M} + \text{H}]^+$ calculated m/z 295.0638; found m/z 295.0650.

4.3.33. 1-(2-Phenyl-1,3-oxazol-4-yl)-1H-benzimidazole (23). The title compound was synthesized according to the general procedure for C–N coupling using 1H-benzimidazole (13.0 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 2:1 to provide **23** as a white solid in 65% yield (16.8 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 7.34–7.45 (m, 2H), 7.58–7.61 (m, 3H), 7.78–7.81 (m, 1H), 7.93–7.97 (m, 1H), 8.07–8.11 (m, 2H), 8.72 (s, 1H), 8.86 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 117.77, 120.83, 123.33, 124.23, 125.53, 126.55, 126.66, 129.0, 131.28, 132.20, 137.52, 141.28, 144.05, 161.18. HRMS (ESI) $\text{C}_{16}\text{H}_{11}\text{N}_3\text{O}$ $[\text{M} + \text{H}]^+$ calculated m/z 262.0980; found m/z 262.0981.

4.3.34. 1-(2-Phenyl-1,3-oxazol-4-yl)-1H-pyrrolo[2,3-*c*]pyridine (24). The title compound was synthesized according to the general procedure for C–N coupling using 6-azaindole (13.0 mg) as the heterocycle. The product was purified by silica gel column chromatography toluene:EtOAc 1:1 to provide **24** as a white solid in 62% yield (16.8 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 6.85 (d, $J = 3.18$ Hz, 1H), 7.60–7.63 (m, 3H), 7.69 (d, $J = 5.38$ Hz, 1H), 8.09 (d, $J = 3.18$ Hz, 1H), 8.10–8.14 (m, 2H), 8.31 (d, $J = 5.38$ Hz, 1H), 8.87 (s, 1H), 9.34 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (400 MHz, $\text{DMSO}-d_6$) δ 104.43, 115.96, 126.62, 126.67, 127.40, 129.80, 130.36, 131.76, 131.99, 134.31, 135.24, 139.51, 140.34, 160.18. HRMS (ESI) $\text{C}_{16}\text{H}_{11}\text{N}_3\text{O}$ $[\text{M} + \text{H}]^+$ calculated m/z 262.0980; found m/z 262.0990.

4.3.35. 1-(1,3-Benzoxazol-2-yl)pyridin-2(1H)-one (25). The title compound was synthesized according to the general procedure for C–N coupling using **1b** and pyridone (11.0 mg) as the heterocycle and stirred for 1 h. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **25** as a white solid in 53% yield (11.5 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 6.47 (br d, $J = 0.98$ Hz, 1H), 6.61 (m, 1H), 7.52 (s, 2H), 7.62–7.69 (m, 1H), 7.83–7.89 (m, 2H), 7.93–7.97 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 106.98, 111.24, 120.33, 122.84, 125.18, 125.88, 135.32, 139.99, 140.75, 150.22, 155.37, 160.90. HRMS (ESI) $\text{C}_{12}\text{H}_8\text{N}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 235.0483; found m/z 235.0483.

4.3.36. 1-(1,3-Benzothiazol-2-yl)pyridin-2(1H)-one (26). The title compound was synthesized according to the general procedure for C–N coupling using **1c** and pyridone (10.5 mg) as the heterocycle and stirred for 3 h. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **26** as a white solid in 77% yield (16.8 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.33 (d, $J = 6.79$ Hz, 1H), 6.72 (d, $J = 7.09$ Hz, 1H), 7.39–7.55 (m, 4H), 7.66 (dd, $J = 7.09$ Hz, 1H), 7.81 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ ppm 6.44–6.51

(m, 1H), 6.80 (d, $J = 9.29$ Hz, 1H), 7.39–7.55 (m, 2H), 7.95 (dd, $J = 16.02$, 8.19 Hz, 1H), 8.98 (dd, $J = 7.34$, 1.71 Hz, 1H). HRMS (ESI) $\text{C}_{12}\text{H}_8\text{N}_2\text{OSNa}$ $[\text{M} + \text{Na}]^+$ calculated m/z 251.0255; found m/z 251.0264.

4.3.37. 1-(1-Benzothiophen-2-yl)pyridin-2(1H)-one (27). The title compound was synthesized according to the general procedure for C–N coupling using **1d** and pyridinone (10.4 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **27** as a white solid in 48% yield (10.5 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.33 (td, $J = 6.79$, 1.34 Hz, 1H), 6.72 (d, $J = 9.29$ Hz, 1H), 7.36–7.45 (m, 4H), 7.66 (dd, $J = 7.09$, 1.96 Hz, 1H), 7.77–7.86 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 106.96, 117.72, 122.09, 122.15, 123.83, 124.75, 125.12, 136.75, 136.79, 138.29, 139.69, 141.18, 161.59. HRMS (ESI) $\text{C}_{13}\text{H}_9\text{NOSNa}$ $[\text{M} + \text{Na}]^+$ calculated m/z 250.0303; found m/z 250.0303.

4.3.38. 1-(5-Phenyl-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one (28). The title compound was synthesized according to the general procedure for C–N coupling using **1e** and pyridinone (10.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **28** as a white solid in 60% yield (13.2 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.33 (t, $J = 6.79$, 1.34 Hz, 1H), 6.72 (m, 1H), 7.36–7.45 (m, 5H), 7.77–7.86 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 107.55, 122.78, 123.44, 127.37, 128.81, 129.44, 130.40, 132.63, 135.69, 141.69, 160.73. HRMS (ESI) $\text{C}_{13}\text{H}_9\text{N}_3\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ calculated m/z 262.0592; found m/z 262.0597.

4.3.39. 1-(1-Phenyl-1H-pyrazol-3-yl)pyridin-2(1H)-one (29). The title compound was synthesized according to the general procedure for C–N coupling using **1f** and pyridinone (10.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **29** as a white solid in 65% yield (14.6 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.29–6.34 (m, 1H), 6.71 (dd, $J = 9.19$, 0.49 Hz, 1H), 7.18 (d, $J = 2.45$ Hz, 1H), 7.31–7.36 (m, 1H), 7.40 (ddd, $J = 9.11$, 6.66, 2.08 Hz, 1H), 7.46–7.52 (m, 2H), 7.71 (dd, $J = 7.82$ Hz, 2H), 7.98 (d, $J = 2.69$ Hz, 1H), 8.14 (dd, $J = 7.09$, 1.96 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 104.12, 106.39, 118.98, 122.05, 126.85, 127.95, 129.56, 135.42, 139.64, 139.78, 149.30, 161.75. HRMS (ESI) $\text{C}_{14}\text{H}_{11}\text{N}_3\text{ONa}$ $[\text{M} + \text{Na}]^+$ calculated m/z 260.0800; found m/z 260.0795.

4.3.40. 1-(2-Phenyl-1,3-thiazol-5-yl)pyridin-2(1H)-one (30). The title compound was synthesized according to the general procedure for C–N coupling using **1g** and pyridinone (10.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **30** as a white solid in 41% yield (10.5 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.38 (td, $J = 6.66$, 1.10 Hz, 1H), 6.75 (d, $J = 9.29$ Hz, 1H), 7.41–7.44 (m, 1H), 7.44–7.49 (m, 3H), 7.70 (dd, $J = 7.09$, 1.96 Hz, 1H), 7.91 (s, 1H), 7.94–7.99 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 107.52, 121.69, 126.35, 129.07, 130.33, 133.37, 134.94, 135.10, 136.13, 139.73, 160.44, 166.69. HRMS (ESI) $\text{C}_{14}\text{H}_{10}\text{N}_2\text{OSH}$ $[\text{M} + \text{H}]^+$ calculated m/z 255.0592; found m/z 255.0592.

4.3.41. 1-(5-Bromo-1-methyl-1H-benzimidazol-2-yl)pyridin-2(1H)-one (31). The title compound was synthesized according to the general procedure for C–N coupling using **1h** and pyridone (11.0 mg) as the heterocycle and stirred for 4 h. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **31** as a white solid in 47% yield (15.0 mg). ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 3.68 (s, 3H),

7.38 (m, 2H), 7.42 ($J = 8.31$, 1H), 7.53 (d, $J = 8.31$, 1H), 7.68 (d, $J = 1.71$, 1H), 8.02 (m, 1H), 8.29 (dd, $J = 1.71$, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 29.06, 99.99, 110.13, 113.31, 115.24, 121.59, 121.77, 125.19, 140.17, 140.40, 148.27, 154.33, 160.27. HRMS (ESI) $\text{C}_{13}\text{H}_{10}\text{BrN}_3\text{ONa}$ [$\text{M} + \text{Na}$] $^+$ calculated m/z 327.9886; found m/z 327.9897.

4.3.42. 1-(5-Phenyl-1,3-oxazol-2-yl)pyridin-2(1H)-one (32). The title compound was synthesized according to the general procedure for C–N coupling using **1i** and pyridinone (10.5 mg) as the heterocycle and stirred for 6 h. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **32** as a white solid in 63% yield (15.1 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.29 (td, $J = 6.72$, 0.73 Hz, 1H), 6.67 (d, $J = 9.29$ Hz, 1H), 7.35 (d, $J = 9.29$, 1H), 7.37–7.46 (m, 4H), 7.58 (dd, $J = 6.72$, 1.96 Hz, 1H), 7.65–7.70 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 106.58, 122.09, 122.55, 124.42, 127.08, 128.97, 129.07, 135.58, 140.70, 151.85, 152.64, 161.13. HRMS (ESI) $\text{C}_{14}\text{H}_{10}\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ calculated m/z 261.0640; found m/z 261.0647.

4.3.43. 1-(2-Phenyl-1,3-oxazol-5-yl)pyridin-2(1H)-one (33). The title compound was synthesized according to the general procedure for C–N coupling using **1j** and pyridinone (10.5 mg) as the heterocycle. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **33** as a white solid in 49% yield (11.7 mg). ^1H NMR (400 MHz, CDCl_3): δ 6.35–6.40 (m, 1H), 6.70 (d, $J = 9.54$ Hz, 1H), 7.39 (ddd, $J = 9.23$, 6.79, 2.08 Hz, 1H), 7.47–7.50 (m, 3H), 7.73–7.76 (s 1H), 7.83 (dd, $J = 7.21$, 1.83 Hz, 1H), 8.02–8.06 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ 107.01, 119.37, 121.90, 126.23, 126.63, 128.93, 130.77, 132.52, 139.15, 143.86, 157.10, 159.70. HRMS (ESI) $\text{C}_{14}\text{H}_{10}\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ calculated m/z 261.0640; found m/z 261.0642.

4.3.44. 1-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)pyridin-2(1H)-one (34). The title compound was synthesized according to the general procedure for C–N coupling using **1k**. The product was purified by silica gel column chromatography Hep:EtOAc 1:1 to provide **34** as opaque oil in 41% yield (9.0 mg). ^1H NMR (400 MHz, CDCl_3): δ 2.44 (s, 3H), 6.29–6.34 (m, 1H), 6.69 (d, $J = 9.54$ Hz, 1H), 7.40–7.50 (m, 4H), 7.57 (dd, $J = 6.97$, 2.08 Hz, 1H), 7.97–8.03 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, $\text{DMSO}-d_6$): δ 11.16, 106.45, 120.94, 126.06, 126.81, 129.74, 131.30, 134.37, 138.92, 141.61, 143.60, 158.15, 160.79. HRMS (ESI) $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ calculated m/z 275.0797; found m/z 275.0794.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.1c00458>.

Experimental details and compound characterization data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

Jay Conrad – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences and Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States; orcid.org/0000-0002-9048-8833; Email: jay.conrad@ucsf.edu

Authors

Cedric Lozano – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States

Cristian Ramirez – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States

Ny Sin – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences and Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States

Hélène M.-F. Viart – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences and Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States

Stanley B. Prusiner – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences and Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, California 94158, United States

Nick A. Paras – Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences and Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California 94158, United States;

orcid.org/0000-0001-5742-4056

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsomega.1c00458>

Notes

Stanley B. Prusiner is a member of the Scientific Advisory Boards of ViewPoint Therapeutics and New Ventures Inc. and a member of the Supervisory Board of Priavoid, none of which have contributed financial or any other support to these studies.

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by a grant from the National Institutes of Health (AG002132) (S.B.P.), as well as by support from the Brockman Foundation (S.B.P.) and the Sherman Fairchild Foundation (S.B.P.).

■ REFERENCES

- (1) Zhang, H.-Z.; Zhao, Z.-L.; Zhou, C.-H. Recent Advance in Oxazole-Based Medicinal Chemistry. *Eur. J. Med. Chem.* **2018**, *144*, 444–492.
- (2) Wasserman, H. H.; Vinick, F. J. Mechanism of the Robinson-Gabriel Synthesis of Oxazoles. *J. Org. Chem.* **1973**, *38*, 2407–2408.
- (3) Robinson, R. CCXXXII.—A New Synthesis of Oxazole Derivatives. *J. Chem. Soc. Dalton* **1909**, *95*, 2167–2174.
- (4) Wipf, P.; Miller, C. P. A new synthesis of highly functionalized oxazoles. *J. Org. Chem.* **1993**, *58*, 3604–3606.
- (5) Zhou, R.-R.; Cai, Q.; Li, D.-K.; Zhuang, S.-Y.; Wu, Y.-D.; Wu, A.-X. Acid-Promoted Multicomponent Tandem Cyclization to Synthesize Fully Substituted Oxazoles via Robinson–Gabriel-Type Reaction. *J. Org. Chem.* **2017**, *82*, 6450–6456.
- (6) Haas, D.; Mosrin, M.; Knochel, P. Regioselective Functionalization of the Oxazole Scaffold Using TMP-Bases of Mg and Zn. *Org. Lett.* **2013**, *15*, 6162–6165.
- (7) Shibahara, F.; Yamauchi, T.; Yamaguchi, E.; Murai, T. One-pot Sequential Direct C–H Bond Arylation of Azoles Catalyzed by

[Pd(phen)₂](PF₆)₂: Synthetic Methods for Triarylated Azoles. *J. Org. Chem.* **2012**, *77*, 8815–8820.

(8) Liégault, B.; Petrov, I.; Gorelsky, S. I.; Fagnou, K. Modulating Reactivity and Diverting Selectivity in Palladium-Catalyzed Heteroaromatic Direct Arylation Through the Use of a Chloride Activating/Blocking Group. *J. Org. Chem.* **2010**, *75*, 1047–1060.

(9) Liégault, B.; Lapointe, D.; Caron, L.; Vlassova, A.; Fagnou, K. Establishment of Broadly Applicable Reaction Conditions for the Palladium-Catalyzed Direct Arylation of Heteroatom-Containing Aromatic Compounds. *J. Org. Chem.* **2009**, *74*, 1826–1834.

(10) Strotman, N. A.; Chobanian, H. R.; Guo, Y.; He, J.; Wilson, J. E. Highly Regioselective Palladium-Catalyzed Direct Arylation of Oxazole at C-2 or C-5 with Aryl Bromides, Chlorides, and Triflates. *Org. Lett.* **2010**, *12*, 3578–3581.

(11) Besselièvre, F.; Lebrequier, S.; Mahuteau-Betzer, F.; Piguel, S. C-H Bond Activation: A Versatile Protocol for the Direct Arylation and Alkenylation of Oxazoles. *Synthesis* **2009**, *2009*, 3511–3518.

(12) Ferrer Flegeau, E.; Popkin, M. E.; Greaney, M. F. Suzuki Coupling of Oxazoles. *Org. Lett.* **2006**, *8*, 2495–2498.

(13) Solomin, V. V.; Radchenko, D. S.; Slobodyanyuk, E. Y.; Geraschenko, O. V.; Vashchenko, B. V.; Grygorenko, O. O. Widely Exploited, Yet Unreported: Regiocontrolled Synthesis and the Suzuki–Miyaura Reactions of Bromooxazole Building Blocks. *Eur. J. Org. Chem.* **2019**, *2019*, 2884–2898.

(14) Strotman, N. A.; Chobanian, H. R.; He, J.; Guo, Y.; Dormer, P. G.; Jones, C. M.; Steves, J. E. Catalyst-Controlled Regioselective Suzuki Couplings at Both Positions of Dihaloimidazoles, Dihalo-oxazoles, and Dihalothiazoles. *J. Org. Chem.* **2010**, *75*, 1733–1739.

(15) Geier, M. J.; Wang, X.; Humphreys, L. D.; Calimsiz, S.; Scott, M. E. Warming Up to Oxazole: Noncryogenic Oxazole Metalation and Negishi Coupling Development. *Synlett* **2019**, *30*, 1776–1781.

(16) Muto, K.; Yamaguchi, J.; Musaev, D. G.; Itami, K. Decarboxylative Organoboron Cross-Coupling of Esters by Nickel Catalysis. *Nat. Commun.* **2015**, *6*, 7508.

(17) Hartwig, J. F.; Richards, S.; Barañano, D.; Paul, F. Influences on the Relative Rates for C–N Bond-Forming Reductive Elimination and β -Hydrogen Elimination of Amides. A Case Study on the Origins of Competing Reduction in the Palladium-Catalyzed Amination of Aryl Halides. *J. Am. Chem. Soc.* **1996**, *118*, 3626–3633.

(18) Zeinali, N.; Oluwoye, I.; Altarawneh, M.; Dlugogorski, B. Z. Kinetics of Photo-Oxidation of Oxazole and its Substituents by Singlet Oxygen. *Sci. Rep.* **2020**, *10*, 3668.

(19) Sather, A. C.; Martinot, T. A. Data-Rich Experimentation Enables Palladium-Catalyzed Couplings of Piperidines and Five-Membered (Hetero)aromatic Electrophiles. *Org. Process Res. Dev.* **2019**, *23*, 1725–1739.

(20) Forero-Cortés, P. A.; Haydl, A. M. The 25th Anniversary of the Buchwald–Hartwig Amination: Development, Applications, and Outlook. *Org. Process Res. Dev.* **2019**, *23*, 1478–1483.

(21) Ruiz-Castillo, P.; Buchwald, S. L. Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions. *Chem. Rev.* **2016**, *116*, 12564–12649.

(22) Antilla, J. C.; Baskin, J. M.; Barder, T. E.; Buchwald, S. L. Copper–Diamine-Catalyzed N-Arylation of Pyrroles, Pyrazoles, Indazoles, Imidazoles, and Triazoles. *J. Org. Chem.* **2004**, *69*, 5578–5587.

(23) Yin, J.; Buchwald, S. L. Palladium-Catalyzed Intermolecular Coupling of Aryl Halides and Amides. *Org. Lett.* **2000**, *2*, 1101–1104.

(24) Surry, D. S.; Buchwald, S. L. Diamine Ligands in Copper-Catalyzed Reactions. *Chem. Sci.* **2010**, *1*, 13–31.

(25) Klapars, A.; Antilla, J. C.; Huang, X.; Buchwald, S. L. A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-Arylation of Nitrogen Heterocycles. *J. Am. Chem. Soc.* **2001**, *123*, 7727–7729.

(26) Monnier, F.; Taillefer, M. Catalytic C–C, C–N, and C–O Ullmann-Type Coupling Reactions. *Angew. Chem., Int. Ed.* **2009**, *48*, 6954–6971.

(27) Altman, R. A.; Buchwald, S. L. Cu-Catalyzed N- and O-Arylation of 2-, 3-, and 4-Hydroxypyridines and Hydroxyquinolines. *Org. Lett.* **2007**, *9*, 643–646.

(28) Altman, R. A.; Buchwald, S. L. 4,7-Dimethoxy-1,10-phenanthroline: An Excellent Ligand for the Cu-Catalyzed N-Arylation of Imidazoles. *Org. Lett.* **2006**, *8*, 2779–2782.

(29) Campeau, L.-C.; Parisien, M.; Jean, A.; Fagnou, K. Catalytic Direct Arylation with Aryl Chlorides, Bromides, and Iodides: Intramolecular Studies Leading to New Intermolecular Reactions. *J. Am. Chem. Soc.* **2006**, *128*, 581–590.

(30) Khambhati, D. P.; Sachinthan, K. A. N.; Rheingold, A. L.; Nelson, T. L. Regioselective Copper-Catalyzed Direct Arylation of Benzodithiophene-S, S-Tetraoxide. *Chem. Commun.* **2017**, *53*, 5107–5109.

(31) Ajitha, M. J.; Pary, F.; Nelson, T. L.; Musaev, D. G. Unveiling the Role of Base and Additive in the Ullmann-Type of Arene-Aryl C–C Coupling Reaction. *ACS Catal.* **2018**, *8*, 4829–4837.

(32) Strieter, E. R.; Blackmond, D. G.; Buchwald, S. L. The Role of Chelating Diamine Ligands in the Goldberg Reaction: A Kinetic Study on the Copper-Catalyzed Amidation of Aryl Iodides. *J. Am. Chem. Soc.* **2005**, *127*, 4120–4121.

(33) Flegeau, E. F.; Popkin, M. E.; Greaney, M. F. Direct Arylation of Oxazoles at C2. A Concise Approach to Consecutively Linked Oxazoles. *Org. Lett.* **2008**, *10*, 2717–2720.

(34) Zhao, X.; Ding, F.; Li, J.; Lu, K.; Lu, X.; Wang, B.; Yu, P. Direct C–H Iodination of 1,3-Azoles Catalyzed by CuBr₂. *Tetrahedron Lett.* **2015**, *56*, 511–513.

(35) Zhang, C.-P.; Wang, Z.-L.; Chen, Q.-Y.; Zhang, C.-T.; Gu, Y.-C.; Xiao, J.-C. Copper-Mediated Trifluoromethylation of Heteroaromatic Compounds by Trifluoromethyl Sulfonium Salts. *Angew. Chem., Int. Ed.* **2011**, *50*, 1896–1900.

(36) Do, H.-Q.; Daugulis, O. A General Method for Copper-Catalyzed Arene Cross-Dimerization. *J. Am. Chem. Soc.* **2011**, *133*, 13577–13586.

(37) Wunderlich, S. H.; Knochel, P. (tmp)₂Zn·2 MgCl₂·2 LiCl: A Chemoselective Base for the Directed Zincation of Sensitive Arenes and Heteroarenes. *Angew. Chem., Int. Ed.* **2007**, *46*, 7685–7688.

(38) Ferrer Flegeau, E.; Popkin, M. E.; Greaney, M. F. Regioselective Palladium Cross-Coupling of 2,4-Dihalo-oxazoles: Convergent Synthesis of Trisoxazoles. *J. Org. Chem.* **2008**, *73*, 3303–3306.

(39) Senadi, G. C.; Hu, W.-P.; Hsiao, J.-S.; Vandavasi, J. K.; Chen, C.-Y.; Wang, J.-J. Facile, Selective, and Regiocontrolled Synthesis of Oxazolines and Oxazoles Mediated by ZnI₂ and FeCl₃. *Org. Lett.* **2012**, *14*, 4478–4481.

(40) Kirsch, P.; Jakob, V.; Oberhausen, K.; Stein, S. C.; Cucarro, I.; Schulz, T. F.; Empting, M. Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8. *J. Med. Chem.* **2019**, *62*, 3924–3939.

(41) Shatila, R. S.; Bouhadir, K. H. Two Simple Protocols for the Preparation of Diallylaminoethyl-Substituted Nucleic Bases: A Comparison. *Tetrahedron Lett.* **2006**, *47*, 1767–1770.

(42) Nagaradja, E.; Chevallier, F.; Roisnel, T.; Dorcet, V.; Halauko, Y. S.; Ivashkevich, O. A.; Matulis, V. E.; Mongin, F. Deprotonation Using a Mixed Lithium–Zinc Base and Computed CH Acidity of 1-Aryl 1H-Benzotriazoles and 1-Aryl 1H-Indazoles. *Org. Biomol. Chem.* **2014**, *12*, 1475–1487.

(43) Damkaci, F.; Alawaed, A.; Vik, E. N-Picolinamides as Ligands for Ullmann-Type C–N Coupling Reactions. *Tetrahedron Lett.* **2016**, *57*, 2197–2200.